CKPT - Checkpoint Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

34.69M

Cash

7.421M

Avg Qtr Burn

-13.18M

Short % of Float

12.65%

Insider Ownership

16.14%

Institutional Own.

15.70%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CK-301 (Cosibelimab) (Anti-PD-L1 Antibody) Details Cutaneous squamous cell carcinoma, Cancer, Solid tumor/s Big Mover™ Suspected Mover™ Susp. Mover™	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Olafertinib (CK-101) (EGFR Inhibitor) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CK-301 (Cosibelimab) (Anti-PD-L1 Antibody) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.